Skip to main content
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: Heart. 2015 Nov 13;102(4):278–284. doi: 10.1136/heartjnl-2015-308403

Table 2.

HFpEF characteristics and medications

Disease related characteristics
NYHA class II 10 (42%)
NYHA class III 10 (42%)
NYHA class IV 4 (17%)
Six min walk distance, m 402 ± 42
B-Type natriuretic peptide, pg/mL 150 ± 26
Diabetes 10 (42%)
COPD 2 (8%)
CAD 6 (25%)
Hypertensive 20 (83%)
Echocardiography Value Reference Range
Ejection fraction, % 62 ± 1 ≥55
LV IVSD, cm 1.1 ± 0.1 0.6 – 1.1
LV PWD, cm 1.1 ± 0.1 0.6 – 0.9
LV ID diastole, cm 4.5 ± 0.2 3.9 – 5.3
LV ID systole, cm 3.0 ± 0.1 2.0 – 4.0
Peak E wave, cm/s 84 ± 7 --
Peak A wave, cm/s 96 ± 11 --
E/A ratio 1.1 ± 0.2 0.6 – 1.32
E' lateral wall, cm/s 7 ± 1 13–28
E/E' ratio 13 ± 2 ≤ 8
Mitral E-wave deceleration time, ms 246 ± 14 142–258
Medications
Beta receptor blocker 11 (46%)
ACEi or ARB 15 (63%)
Loop diuretics 22 (92%)
Aldosterone antagonist 16 (67%)
Statin 18 (75%)
Nitrates 5 (21%)
Calcium channel blockers 3 (13%)

HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart Association; LV IVSD, left ventricle interventricular septum diameter; LV PWD, left ventricle posterior wall diameter; LV ID, left ventricle internal diameter; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. Data are mean ± SEM or % of group.

HHS Vulnerability Disclosure